The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -32.08 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -4.43 — no flag raisedOK
- Earnings quality 86/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as AVITA Medical, Inc. reports it. History and quarterly detail are in the app.
- Recell System$66.5M
- Recell Go Preparation Kit$35.8M
- Permeaderm$6.0M
- Other Wound Care Products$4.2M
- Lease Revenue$731K
Leadership changes
From AVITA Medical, Inc.'s own filings, the day they're filed.
- Jan Stern Reed · Director · appointmenteff. 2026-04-30
- Cary Vance · President · appointmenteff. 2026-04-30
- K. Joe Woody · appointmenteff. 2026-01-01
Latest filings
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-06-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AVITA Medical, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when AVITA Medical, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.